Biopharma Co. Misled Investors On Cancer Drug Progress: Suit

Law360, Los Angeles (October 31, 2013, 4:54 PM EDT) -- Vical Inc., which researches and develops biopharmaceutical products for the prevention and treatment of serious diseases, on Wednesday was hit with a putative class action in California federal court by a shareholder who says the company made false statements about the progress of cancer drug Allovectin-7.

Named plaintiff Joel Duncan, who seeks to represent investors who acquired Vical securities between Feb. 8, 2012, and Aug. 12, says Vical and certain of its officers and directors violated the Securities Exchange Act of 1934 by issuing materially false...
To view the full article, register now.




Case Information

Case Title

Duncan v. Vical Incorporated et al

Case Number



California Southern

Nature of Suit



Cynthia Bashant

Date Filed

October 30, 2013


Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.